Abbott completes AMO acquisition

Article

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Scott Stoffel, director of financial and litigation communications at Abbott remarked, "Our four major business divisions all delivered double-digit percentages of growth during the past year, resulting in 14% growth of our full-year 2008 sales. This leaves us in a very confident position for purchasing AMO, which is a global leader in eye-care devices."

As a subsidiary of Abbott, AMO will now be known as Abbott Medical Optics. The sales representatives, customer service team and pricing and ordering structure will remain the same.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.